Zymeworks Up 10% On Positive Study Results Of Zanidatamab In Biliary Tract Cancer Treatment

On:

Shares of Zymeworks Inc. (ZYME) are rising more than 10% Monday morning after reporting positive topline results from the Phase 2b study of zanidatamab in patients with biliary tract cancers.

Topline results from the Phase 2b HERIZON-BTC-01 study showed that 41.3% of enrolled patients with HER2-amplified and expressing disease achieved an objective response after treatment with zanidatamab.

Full results from the study are expected to be presented in 2023.

ZYME is at $7.17 currently. It has traded in the range of $4.11-$17.27 in the last 1 year.

Source: Read Full Article

Lates News:
  1. Bitcoin At Risk Of 50% Drop Before Next Halving If Historical Trend Repeats, Warns Influential Crypto Guru
  2. Cryptos Muted Ahead Of Key Economic Data Updates
  3. This Bitcoiner Just Paid a Whopping $500,000 In Transaction Fees for A 0.074 BTC Transfer
  4. Coinbase to Launch Institutional BTC and ETH Futures
  5. Pfizer Boosts FY22 Outlook As Q3 Results Top Estimates